Literature DB >> 22521610

Gender-specific reduction of hepatic Mrp2 expression by high-fat diet protects female mice from ANIT toxicity.

Bo Kong1, Iván L Csanaky, Lauren M Aleksunes, Meghan Patni, Qi Chen, Xiaochao Ma, Hartmut Jaeschke, Scott Weir, Melinda Broward, Curtis D Klaassen, Grace L Guo.   

Abstract

Emerging evidence suggests that feeding a high-fat diet (HFD) to rodents affects the expression of genes involved in drug transport. However, gender-specific effects of HFD on drug transport are not known. The multidrug resistance-associated protein 2 (Mrp2, Abcc2) is a transporter highly expressed in the hepatocyte canalicular membrane and is important for biliary excretion of glutathione-conjugated chemicals. The current study showed that hepatic Mrp2 expression was reduced by HFD feeding only in female, but not male, C57BL/6J mice. In order to determine whether down-regulation of Mrp2 in female mice altered chemical disposition and toxicity, the biliary excretion and hepatotoxicity of the Mrp2 substrate, α-naphthylisothiocyanate (ANIT), were assessed in male and female mice fed control diet or HFD for 4weeks. ANIT-induced biliary injury is a commonly used model of experimental cholestasis and has been shown to be dependent upon Mrp2-mediated efflux of an ANIT glutathione conjugate that selectively injures biliary epithelial cells. Interestingly, HFD feeding significantly reduced early-phase biliary ANIT excretion in female mice and largely protected against ANIT-induced liver injury. In summary, the current study showed that, at least in mice, HFD feeding can differentially regulate Mrp2 expression and function and depending upon the chemical exposure may enhance or reduce susceptibility to toxicity. Taken together, these data provide a novel interaction between diet and gender in regulating hepatobiliary excretion and susceptibility to injury.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22521610      PMCID: PMC3371772          DOI: 10.1016/j.taap.2012.04.001

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  26 in total

1.  Tissue distribution and hepatic and renal ontogeny of the multidrug resistance-associated protein (Mrp) family in mice.

Authors:  Jonathan M Maher; Angela L Slitt; Nathan J Cherrington; Xingguo Cheng; Curtis D Klaassen
Journal:  Drug Metab Dispos       Date:  2005-03-31       Impact factor: 3.922

2.  Mutations in the canilicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/Dubin-Johnson syndrome.

Authors:  M Wada; S Toh; K Taniguchi; T Nakamura; T Uchiumi; K Kohno; I Yoshida; A Kimura; S Sakisaka; Y Adachi; M Kuwano
Journal:  Hum Mol Genet       Date:  1998-02       Impact factor: 6.150

3.  Polymorphisms of MRP2 (ABCC2) are associated with susceptibility to nonalcoholic fatty liver disease.

Authors:  Silvia Sookoian; Gustavo Castaño; Tomas Fernández Gianotti; Carolina Gemma; Carlos Jose Pirola
Journal:  J Nutr Biochem       Date:  2008-10-15       Impact factor: 6.048

4.  Experimental cholangitis due to alpha-naphthyl-isothiocyanate (ANIT).

Authors:  S GOLDFARB; E J SINGER; H POPPER
Journal:  Am J Pathol       Date:  1962-06       Impact factor: 4.307

5.  Gender-related differences in expression and function of hepatic P-glycoprotein and multidrug resistance-associated protein (Mrp2) in rats.

Authors:  Tatsuya Suzuki; Ying Lan Zhao; Masayuki Nadai; Kazumasa Naruhashi; Akemi Shimizu; Kenji Takagi; Kenzo Takagi; Takaaki Hasegawa
Journal:  Life Sci       Date:  2006-02-17       Impact factor: 5.037

6.  Oxidative and electrophilic stress induces multidrug resistance-associated protein transporters via the nuclear factor-E2-related factor-2 transcriptional pathway.

Authors:  Jonathan M Maher; Matthew Z Dieter; Lauren M Aleksunes; Angela L Slitt; Grace Guo; Yuji Tanaka; George L Scheffer; Jefferson Y Chan; Jose E Manautou; Ying Chen; Timothy P Dalton; Masayuki Yamamoto; Curtis D Klaassen
Journal:  Hepatology       Date:  2007-11       Impact factor: 17.425

Review 7.  Effect of obesity on the pharmacokinetics of drugs in humans.

Authors:  Michael J Hanley; Darrell R Abernethy; David J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

8.  Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease.

Authors:  Andrew J Lickteig; Craig D Fisher; Lisa M Augustine; Lauren M Aleksunes; David G Besselsen; Angela L Slitt; Jose E Manautou; Nathan J Cherrington
Journal:  Drug Metab Dispos       Date:  2007-07-19       Impact factor: 3.922

9.  Drug-metabolizing enzyme and transporter expression in a mouse model of diabetes and obesity.

Authors:  Qiuqiong Cheng; Lauren M Aleksunes; José E Manautou; Nathan J Cherrington; George L Scheffer; Hideki Yamasaki; Angela L Slitt
Journal:  Mol Pharm       Date:  2008-01-12       Impact factor: 4.939

10.  The hepatic metabolism and biliary excretion of benzo[a]pyrene in guinea-pigs fed normal, high-fat or high-cholesterol diets.

Authors:  S G Bowes; A G Renwick
Journal:  Xenobiotica       Date:  1986-06       Impact factor: 1.908

View more
  4 in total

Review 1.  The impact of drug transporters on adverse drug reaction.

Authors:  Yan Zhou; Guo-Qiang Zhang; Yu-Hui Wei; Jian-Ping Zhang; Guo-Rong Zhang; Jiang-Xia Ren; Hao-Gang Duan; Zhi Rao; Xin-An Wu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-01-22       Impact factor: 2.441

Review 2.  Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women.

Authors:  Flavia Franconi; Ilaria Campesi
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

3.  Differential regulation of hepatic organic cation transporter 1, organic anion-transporting polypeptide 1a4, bile-salt export pump, and multidrug resistance-associated protein 2 transporter expression in lymphocyte-deficient mice associates with interleukin-6 production.

Authors:  Connor E Bodeman; Anika L Dzierlenga; Catherine M Tally; Ryan M Mulligan; April D Lake; Nathan J Cherrington; Susan C McKarns
Journal:  J Pharmacol Exp Ther       Date:  2013-08-08       Impact factor: 4.030

4.  SRT1720 Alleviates ANIT-Induced Cholestasis in a Mouse Model.

Authors:  Linxi Yu; Xiaoxin Liu; Zihang Yuan; Xiaojiaoyang Li; Hang Yang; Ziqiao Yuan; Lixin Sun; Luyong Zhang; Zhengzhou Jiang
Journal:  Front Pharmacol       Date:  2017-05-11       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.